Vanda Pharmaceuticals Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $VNDA in the last 30 days.
See all $VNDA insider activity →U.S. stock futures fell early Monday due to tariff uncertainty and Iran tensions. Nasdaq, S&P 500, and Dow futures declined 0.5%-0.6%. Nvidia's earnings, Netflix's board controversy, and Honeywell's acquisition are in focus. Precious metals rose, with gold above $5,100 and silver near $88/oz.
Vanda Pharmaceuticals (VNDA) announced FDA acceptance of its Biologics License Application for Imsidolimab, a treatment for Generalized Pustular Psoriasis (GPP). The company reported positive results from clinical trials, with over 50% of patients achieving clear or almost clear skin. VNDA shares rose nearly 5% in pre-market trading.
Vanda Pharmaceuticals (VNDA) received Orphan Designation from the European Commission for imsidolimab, a treatment for Generalized Pustular Psoriasis (GPP). The drug also has similar designations in the US and Japan. The FDA is reviewing the Biologics License Application with a target action date of December 12, 2026.
Over the past 7 days, alphai's AI scored 1 news story mentioning VNDA (Vanda Pharmaceuticals Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent VNDA coverage spans regulation, market movers and earnings.
Regulatory approval adds a new product line.
Regulatory acceptance signals near‑term upside potential if approval follows.
The designation may boost Vanda's valuation by enhancing the drug's market potential and securing regulatory incentives.
Minor ownership disclosure with limited immediate price impact.
Regulatory approval unlocks commercial launch and revenue potential, supporting a sharp price jump.
alphai scores every news story that mentions VNDA with an AI model for sentiment and relevance, and aggregates insider trades from Vanda Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
U.S. stock futures fell early Monday due to tariff uncertainty and Iran tensions. Nasdaq, S&P 500, and Dow futures declined 0.5%-0.6%. Nvidia's earnings, Netflix's board controversy, and Honeywell's acquisition are in focus. Precious metals rose, with gold above $5,100 and silver near $88/oz.
2 min readVanda Pharmaceuticals (VNDA) announced FDA acceptance of its Biologics License Application for Imsidolimab, a treatment for Generalized Pustular Psoriasis (GPP). The company reported positive results from clinical trials, with over 50% of patients achieving clear or almost clear skin. VNDA shares rose nearly 5% in pre-market trading.
1 min readVanda Pharmaceuticals (VNDA) received Orphan Designation from the European Commission for imsidolimab, a treatment for Generalized Pustular Psoriasis (GPP). The drug also has similar designations in the US and Japan. The FDA is reviewing the Biologics License Application with a target action date of December 12, 2026.
2 min readMillennium Management LLC and related entities report a 5.6% passive stake in Vanda Pharmaceuticals (VNDA), owning 3.38M shares. They share voting and disposal power but deny sole beneficial ownership. The filing is made under a joint agreement.
1 min readVanda Pharmaceuticals (VNDA) shares surged 38% after the FDA approved Bysanti for treating bipolar I disorder and schizophrenia. The drug is expected to launch in Q3 2026. VNDA also has another drug, Nereus, approved for motion sickness, but faced rejection for Hetlioz in treating jet lag. Retail sentiment on Stocktwits turned 'extremely bullish'.
2 min readVanda Pharmaceuticals (VNDA) stock surged 40% after FDA approved its Bysanti tablets for bipolar I disorder and schizophrenia. Analysts' price targets range from $7.5 to $22, with an average of $13.63. The company expects Bysanti to launch in Q3 2026 and has other drugs in development.
4 min readVanda Pharmaceuticals said the FDA approved BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia in Q1 2026, and it plans a commercial launch in the second half of 2026. U.S. data exclusivity runs to Feb 20, 2031, with patents to May 31, 2044. Vanda reported Q2 net product sales of $50.5M and expects Phase III readouts before year-end 2026.
6 min readVanda Pharmaceuticals (VNDA) said its motion sickness drug Nereus is now commercially available across the U.S., after FDA approval in December for preventing vomiting in adults. Vanda estimates motion sickness affects 25% to 30% of adults. Nereus is offered via direct-to-consumer and retail pharmacies, with a $85 cash-pay dose versus a $255 list price. VNDA shares rose about 4% after hours.
3 min readVanda Pharmaceuticals (VNDA) reported weaker Q2 results, with revenue down 18% to $51m versus analyst estimates. Statutory loss was $1.04 per share, 77% worse than expected. Four analysts cut the consensus 12-month price target 12% to $12.44 and lowered revenue forecasts, while 2026 revenue consensus is $253.5m.
5 min readVanda Pharmaceuticals reported Q2 2026 drivers on its earnings call. Fanapt prescriptions rose 31% vs Q2 2025, while Hetlioz revenue fell 66% due to generic competition and a $7M shipment timing delay. Management cited higher operating expenses from four Phase 3 programs. It expects 2026 revenue growth of 23% at the midpoint, dependent on BYSANTI and NEREUS launch, and said cash should fund operations through end-2027.
6 min read
